Day 1 Recap: #ACR25 Highlights Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope and Jack Cush as they discuss highlights and key takeaways from the Day 1 Recap on Sunday, October 26th. https://t.co/Kq8TDBLUYZ https://t.co/TNM8ZAji9w

• Day 1 Recap: ACR Convergence 2025 Highlights | RheumNow

CAR T Which cells to target What patients & what disease When is right time In vivo (new) ex vivo Premeds immune suppression What to use, ?if anything Cons Is it safe ?long term effectiveness What is failure rate ICANs and other side effects #ACRBest #ACR25 @RheumNow #26S21 https://t.co/TUSJh1hrPr https://t.co/JiqYzgBmYP

• https://x.com/Janetbirdope/status/1983902022501081162/photo/1
• https://x.com/Janetbirdope/status/1983902022501081162/photo/1
• https://twitter.com/Janetbirdope/status/1983901002677023202

Needle in a haystack What T cell to target for #autoimmune diseases T cell repetoires (TCR) not all are sequenced and many can exist to present antigens Diff scales of approaches Implications CAR-T CD19 CD20 BCMA Treg HLAB27 etc! #ACR25 @ACRheum @RheumNow Alok Joglekar #26S08 https://t.co/Qgw8Akz1xk

• https://x.com/Janetbirdope/status/1983899020561973282/photo/1
• https://x.com/Janetbirdope/status/1983899020561973282/photo/1
• https://x.com/Janetbirdope/status/1983899020561973282/photo/1

Prospective RCT on safety & efficacy of TAC+GC vs. MMF+GC TAC+GC was comparable to MMF+GC as continuous induction maintenance treatment over 96 wks for LN. AE rates comparable. TAC - AKI & tremor MMF - leucopenia reassuring data.more tx options. #ACR25 @RheumNow Abs2697 https://t.co/16Fd8zE5dL

• https://x.com/RHEUMarampa/status/1983852449321656332/photo/1

So what's been tried for ICANS, knowing that it's unlikely that one therapy will fix all of it? @CarolineDiorio @ChildrensPhila in the #ACR25 BCRC pre-meeting @RheumNow https://t.co/10wdkrH29s

• https://x.com/drdavidliew/status/1983734614247215351/photo/1
• https://x.com/drdavidliew/status/1983734614247215351/photo/1

Toxicity is the big question about CAR-T in RA - what did the CRS/ICANS profile look like in this German ph1 in RA? Pretty good so far - but obviously will be under enormous scrutiny when we are looking at diseases with good existing therapies #ACR25 ABST0471 @RheumNow https://t.co/xXyzOwLvx8

• https://x.com/drdavidliew/status/1983726261177667701/photo/1

2465: Dual-target CD19/BCMA CAR-T in refractory SLE (Phase 1) 🔹All pts (n=10) met SRI-4 by wk24 🔹DORIS remission: 5 (wk24), 6 (wk36–48) 🔹Residual proteinuria (n=4); renal bx (n=3) showed resolved IC deposits & inflammation 🔹CRS Grade 1 (n=6); no ICANS @RheumNow #ACR25

What does the FDA regulatory approach look like for CAR-T and T cell engages right now? The FDA session at #ACR25 gave some clues @RheumNow https://t.co/wHNnNTrXaE

• https://x.com/drdavidliew/status/1983725446526332969/photo/1
• https://x.com/drdavidliew/status/1983725446526332969/photo/1

LB23: Regulate-RA- ongoing Phase 1 trial of autologous CAR-Tregs in refractory RA (no lymphodepletion) 🔹 4/6 pts had ↓ DAS28-CRP by wk 4 with rapid onset & ↓ joint counts at dose level 2 🔹 Synovial biopsies to date showed ↓ inflammatory score post-tx @RheumNow #ACR25 https://t.co/JMBbLIEmJG

• https://x.com/AkhilSoodMD/status/1983716797330419864/photo/1

LB04: Another approach to CAR-T, CD20+/BCMA bispecific CAR-T in refractory proliferative LN: 🔹100% discontinued biologics & IS at follow-up 🔹Renal response ~78% 🔹CRS mostly Grade 1–2 (~70%); ≥Grade 3 AEs = transient & hematologic @RheumNow #ACR25 https://t.co/oNK4wtLGYV

• https://x.com/AkhilSoodMD/status/1983713052618080271/photo/1
• https://x.com/AkhilSoodMD/status/1983713052618080271/photo/1

#ACR25 Please find my blog on update and progress of clinical trials in #Sjogren #SjD @RheumNow https://t.co/u8pxZ5FeBX https://t.co/KAnRo3Zqnz

• Sjogren’s disease: two drugs with positive trials | RheumNow
• https://x.com/Yuz6Yusof/status/1983706922437296619/photo/1

Abstract 1563: Ongoing Phase 1/2 trial of Rese-cel CAR-T in systemic sclerosis 🔹Pt with severe skin involvement showed improvement in mRSS (42→34), PFTs & nailfold capillaroscopy at 6 mo 🔹Grade 2 CRS, no ICANS or DLT reported Early but exciting findings @RheumNow #ACR25

While post-CAR-T CRS might be semi-familiar for rheumatologists, ICANS is a new concept to get our heads around, and one which is far from heterogenous. @CarolineDiorio @ChildrensPhila in the #ACR25 BCRC pre-meeting @RheumNow https://t.co/qX2jKMG2oB

• https://x.com/drdavidliew/status/1983705100066648157/photo/1